USE OF ACTIVATED BLOOD COAGULATION FACTOR VII FOR TREATMENT OF EXTENSIVE BLOODINGS CAUSED BY THROMBOLYTIC THERAPY

摘要

FIELD: clinical hematology. ^ SUBSTANCE: invention, in particular, is dealing with using activated blood coagulation factor VII (VIIa) when treating extensive bloodings caused by thrombolytic/fibrinolytic therapy, including intracranial hemorrhages, and to corresponding treatment method. ^ EFFECT: obtained desired result at low undesired effect occurrence in patients suffering from indicated bloodings. ^ 10 cl, 3 dwg